Near East University, Faculty of Medicine, Division of Pediatric Allergy & Immunology, Nicosia, Cyprus.
University of Kyrenia, Faculty of Medicine, Division of Immunology, Kyrenia, Cyprus.
Immunotherapy. 2020 Jun;12(8):577-585. doi: 10.2217/imt-2019-0182. Epub 2020 May 21.
Allergy immunotherapy (AIT) is currently the only disease-modifying treatment for allergic-respiratory diseases. Polysensitization may increase the severity of current disease resulting in subsequent asthma development in patients with allergic rhinitis. Due to the absence of general recommendations for the practical approach to polysensitized patients, clinical management is not standardized. The correlation between sensitizations and clinical symptoms, elimination of possible pollen cross-reactivities and principles of homologous allergen groups will guide the allergists to deduce the most relevant allergens for AIT. In the highlight of the previously proposed approach strategies to polyallergic patients, hereby we propose a revised practical stepwise approach based on the current European Medicine Agency (EMA) guidelines. However, more supporting data from well-designed, controlled, future studies are needed to improve clinical management recommendations for AIT in polyallergic patients.
变应原免疫治疗（AIT）是目前治疗变应性呼吸道疾病的唯一具有疾病修饰作用的治疗方法。多致敏可能会增加现有疾病的严重程度，导致变应性鼻炎患者随后发生哮喘。由于缺乏针对多敏患者的实用方法的一般建议，因此临床管理尚未标准化。致敏与临床症状之间的相关性、消除可能的花粉交叉反应性以及同源变应原组的原则将指导过敏症专家推断出最相关的 AIT 变应原。在之前提出的多敏患者方法策略的重点中，我们在此基于当前的欧洲药品管理局（EMA）指南提出了一种修订后的实用分步方法。然而，需要更多来自精心设计的、对照的未来研究的支持数据，以改善多敏患者 AIT 的临床管理建议。
